Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy

Accept / Decline

Press releases

Ferring Acquires DUPOMAR

Lausanne, Switzerland
January 12th, 2004

The acquisition reinforces Ferring's commitment to Latin America and strengthens the company in the field of women's health.

Ferring Pharmaceuticals announced today that it has acquired the Argentinean company DUPOMAR S.A, which will immediately double Ferring's turnover in Argentina and enable the company to propel its operation there to the next level.

DUPOMAR specializes in women's and children's health and provides Ferring with an additional sales force of more than 60 representatives covering the entire country. "With a stronger presence we can establish a dedicated infertility field force, and be in a good position to focus on coverage beyond the urban centers covered by the existing Ferring sales force," says Michel L. Pettigrew, Chief Operating Officer.

DUPOMAR's products are sold exclusively in Argentina and fit well with Ferring's therapeutic areas. In particular they will strengthen Ferring's business in the area of women's health, an area which has been growing since Ferring introduced its infertility line in Argentina in 2001.

A new business organization is underway to maximize the synergies between Ferring and DUPOMAR for the benefit of the combined portfolio. "We are happy to welcome the new members of our sales team, and give them the opportunity to work in an international and successful organisation and to promote high tech, quality products," says Alberto Perez, who will head Ferring-DUPOMAR.

With a 40 year long history DUPOMAR is well known in Argentina. "DUPOMAR has an outstanding reputation for trust and quality, which we in Ferring are happy to cultivate and continue," says Michel L. Pettigrew. 

Ferring started its business in Argentina in 1993 and the subsequent introduction of its infertility line led to excellent results in 2002, with the company achieving the highest Evolution Index in the Argentinean market. After the acquisition Ferring-DUPOMAR has more than130 employees in Argentina.

It is Ferring's ambition to further develop its business in Latin America and this acquisition demonstrates that Ferring is committed to expanding its presence in both the therapeutic areas and key geographies in which the company operates. 
Notes to editors:

DUPOMAR S.A. is a US $6 million pharmaceutical company in Argentina that specializes in women's and children's health, including treatments for urinary infections, osteoporosis/calcium deficit, pain and inflammation management.  Key physician targets covered by DUPOMAR include the Gynecologist, Pediatrician, Ear - Nose -Throat (ENT) and General Practitioner (GP). 
The production facility is based in Buenos Aires, as are the DUPOMAR commercial headquarters.

Ferring is a research driven, speciality biopharmaceutical group active in global markets.  The company identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, gynecology, infertility and urology.

In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in over 40 countries.

To learn more about Ferring or our products please visit us at: www.Ferring.com

For more information, please contact:
Mette Nikolajsen
Ferring International Center
Telephone: + 45 28 78 71 98
Email: mette.nikolajsen@ferring.com

See more Press releases



TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10


Global Locator